Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview 10
Therapeutics Development 11
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Stage of Development 11
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Therapy Area 12
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Indication 13
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Companies 18
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Universities/Institutes 24
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment 26
Assessment by Monotherapy/Combination Products 26
Assessment by Mechanism of Action 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 32
Acetylon Pharmaceuticals, Inc. 32
Chong Kun Dang Pharmaceutical Corp. 34
Curis, Inc. 35
HitGen LTD 36
Kancera AB 37
Karus Therapeutics Limited 38
Lycera Corp. 39
Merck & Co., Inc. 40
Millennium Pharmaceuticals Inc 41
OncoHoldings, Inc. 42
OnKure Inc 43
Quimatryx, S.L. 44
Sigma-Tau S.p.A. 45
SK Biopharmaceuticals Co., Ltd. 46
Takeda Pharmaceutical Company Limited 47
TetraLogic Pharmaceuticals 48
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles 49
ACY-738 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ACY-775 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
C-1A - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
citarinostat - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
CKD-504 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CKD-506 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CKD-L - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CUDC-907 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HG-3001 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
IKH-12 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
KA-2507 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
KAN-0439221 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
KAN-0439782 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
KAR-3000 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
MPT-0B291 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
N-140 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Nexturastat A - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ONCO-101 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
QTX-100 Series - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
QTX-102 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
QTX-125 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
QTX-153 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
remetinostat - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
ricolinostat - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to HDAC6 HDAC6 for Sepsis - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecule to Inhibit HDAC6 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecules to Inhibit HDAC6 for Autoimmune Diseases - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
ST-3595 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
vorinostat - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Projects 103
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Featured News & Press Releases 106
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 106
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 107
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 107
Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 108
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 109
Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 109
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 111
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 111
Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma 111
Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma 113
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 115
Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models 117
Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 118
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 119
Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma 119
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Products under Development by Companies, H2 2016 (Contd..3) 22
Products under Development by Companies, H2 2016 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Products under Investigation by Universities/Institutes, H2 2016 25
Assessment by Monotherapy/Combination Products, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 32
Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 34
Pipeline by Curis, Inc., H2 2016 35
Pipeline by HitGen LTD, H2 2016 36
Pipeline by Kancera AB, H2 2016 37
Pipeline by Karus Therapeutics Limited, H2 2016 38
Pipeline by Lycera Corp., H2 2016 39
Pipeline by Merck & Co., Inc., H2 2016 40
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 41
Pipeline by OncoHoldings, Inc., H2 2016 42
Pipeline by OnKure Inc, H2 2016 43
Pipeline by Quimatryx, S.L., H2 2016 44
Pipeline by Sigma-Tau S.p.A., H2 2016 45
Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 46
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 47
Pipeline by TetraLogic Pharmaceuticals, H2 2016 48
Dormant Projects, H2 2016 103
Dormant Projects (Contd..1), H2 2016 104
Dormant Projects (Contd..2), H2 2016 105